This statistic shows the amount of registrations of newly diagnosed cases of skin cancer in England in 2022, by age group and gender. Almost *** thousand new cases were recorded among men aged 75 to 79 years of age. It should be noted that the number of people in England in each age group varies and is therefore not necessarily a reflection of susceptibility to skin cancer.

This publication reports on newly diagnosed cancers registered in England in addition to cancer deaths registered in England during 2020. It includes this summary report showing key findings, spreadsheet tables with more detailed estimates, and a methodology document.

In 2016 to 2018, Wales had the highest incidence of melanoma skin cancer in the United Kingdom, with a diagnosis rate of **** cases per 100,000 for men and **** cases per 100,000 women. The incidence rates in England are slightly lower compared to Wales, while in that year Northern Ireland had lowest rate of skin cancer.

This statistic shows the rate of registrations of newly diagnosed cases of skin melanoma per 100,000 population in England in 2020, by region and gender. In this year, the rate of newly diagnosed cases of skin cancer among women was highest in the West Midlands region of England at 28.3 cases per 100,000 population, whereas the highest rate among men was in North West at 31.7 per 100,000 population

Legacy unique identifier: P00655

Cancer registrations for all skin cancers per 100,000 population. Directly standardised registration rate Source: Regional Cancer Registries, Office for National Statistics (ONS). Publisher: Information Centre (IC) - Clinical and Health Outcomes Knowledge Base Geographies: Local Authority District (LAD), Government Office Region (GOR), National, Strategic Health Authority (SHA) Geographic coverage: England Time coverage: 2004-2006 Type of data: Administrative data

In the period 2016 and 2018, the incidence of non-melanoma skin cancer diagnoses in the United Kingdom was ***** cases per 100,000 for men and ***** cases per 100,000 women. The rate of non-melanoma skin cancer has increased significantly in the UK since 1993, when the rate was around ** cases per 100,000 women and *** per 100,000 for men.

In 2022, the number of new skin melanoma cases in England was 35.5 per 100,000 for males and 29 per 100,000 for females. This marked the highest rate of newly diagnosed malignant melanoma cases for both genders during the analyzed years. This statistic shows the rate of newly diagnosed cases of skin melanoma cancer per 100,000 population in England from 1995 to 2022, by gender.

Snapshot img

Non-Melanoma Skin Cancer Market Size 2024-2028

The non-melanoma skin cancer market size is forecast to increase by USD 136.9 million at a CAGR of 4.5% between 2023 and 2028.

The non-melanoma skin cancer (NMSC) market is experiencing significant growth due to the increasing incidence of this type of cancer. NMSC is the most common form of cancer, with over three million cases diagnosed annually worldwide. The market is facing a challenge due to the lack of drugs in the pipeline for NMSC treatment. This trend is expected to continue, as current treatments such as surgical excision and Mohs micrographic surgery have limitations and may leave scars or require multiple procedures. Healthcare services are playing a critical role in addressing this issue by improving early detection, offering advanced treatment options, and providing patient support throughout the recovery process. Additionally, the aging population and rising awareness about cosmetic skin care are contributing to the market's growth. The market analysis report provides an in-depth analysis of these trends and growth factors, offering valuable insights for stakeholders In the healthcare industry.

What will be the Size of the Non-Melanoma Skin Cancer Market During the Forecast Period?

Request Free Sample

The market encompasses a range of conditions, including basal cell carcinoma and squamous cell carcinoma. These forms of cancer are primarily caused by sun exposure, resulting in symptoms such as scaly surfaces, red patches, sores, moles, or warts. Treatment modalities include surgery, radiation therapy, photodynamic therapy, topical therapies, cryosurgery, and electrodesiccation. Mohs surgery, a specialized form of surgery, is increasingly utilized for high-risk occurrences due to its ability to preserve healthy tissue.
Advanced treatments, such as Vismodegib, offer promising alternatives for patients with recurrent or metastatic disease. The market is driven by the increasing prevalence of sun exposure-related injuries and the growing aging population. Despite advancements in treatment options, the risk of recurrence remains a significant concern, necessitating ongoing research and innovation.

How is this Non-Melanoma Skin Cancer Industry segmented and which is the largest segment?

The non-melanoma skin cancer industry research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in 'USD million' for the period 2024-2028, as well as historical data from 2018-2022 for the following segments.

Type

  BCC
  SCC


Geography

  North America

    Canada
    US


  Europe

    Germany
    UK


  Asia

    China
    Japan


  Rest of World (ROW)

By Type Insights

The bcc segment is estimated to witness significant growth during the forecast period.

Non-Melanoma Skin Cancer (NMSC), primarily comprised of Basal Cell Carcinoma (BCC) and Squamous Cell Carcinoma (SCC), accounts for a significant portion of cancer occurrences worldwide. BCC, responsible for approximately 80% of NMSC, has seen an annual growth rate of 2% In the US and 5% in Europe. In the Asia Pacific region, Australia holds the highest incidence of BCC among individuals aged 70. Despite a low mortality rate of approximately 0.05%, BCCs can result in disfiguring body alterations. Surgical treatments, including Mohs surgery, cryosurgery, and electrodesiccation, are common interventions. Radiation therapy, photodynamic therapy, and topical therapies also serve as alternative treatment methods.

Get a glance at the Non-Melanoma Skin Cancer Industry report of share of various segments Request Free Sample

The BCC segment was valued at USD 410.20 million in 2018 and showed a gradual increase during the forecast period.

Regional Analysis

North America is estimated to contribute 29% to the growth of the global market during the forecast period.

Technavio's analysts have elaborately explained the regional trends and drivers that shape the market during the forecast period.

For more insights on the market share of various regions, Request Free Sample

Non-Melanoma Skin Cancer (NMSC), comprised primarily of Basal Cell Carcinoma (BCC) and Squamous Cell Carcinoma (SCC), is a significant health concern In the US, accounting for approximately 35-45% of all cancers among Caucasians. NMSC is the most common cancer type In the US, with BCC being the most prevalent skin cancer subtype. Treatment modalities for NMSC include surgery, radiation therapy, photodynamic therapy, topical therapies, cryosurgery, electrodesiccation, Mohs surgery, Vismodegib for advanced cases, and chemotherapy for metastasis. Risk factors for NMSC include sun exposure, sunburns, radiation exposure, inflammation, injury, and the presence of skin growths such as bumps, moles, red patches, sores, moles, warts, and recurrence.

Market Dynamics

Our researchers analyzed the data with 2023 a

In the years 2016 to 2020, over ** percent of patients diagnosed with melanoma of the skin in England aged between 15 and 44 years of age would survive for at least one year, while patients this age had a five-year survival rate of nearly ** percent. The survival rates for melanoma of the skin did generally fall if the patient was older when diagnosed.

This dataset presents information on five-year survival rates from all cancers, focusing on individuals diagnosed with invasive cancers (ICD-10 codes C00 to C97, excluding non-melanoma skin cancer C44). It provides a simplified local methodology for calculating survival outcomes, enabling analysis by ethnicity, deprivation, and within the Birmingham and Solihull (BSol) geography. While it does not replicate the national calculation, it offers valuable insights into cancer survival trends at a more granular level.

Rationale

The primary aim of this indicator is to increase five-year survival rates from all cancers. Monitoring survival over a five-year period provides a meaningful measure of cancer outcomes and the effectiveness of early diagnosis and treatment interventions.

Numerator

The numerator includes individuals who were diagnosed with a specific type of cancer and subsequently died from the same type of cancer within five years of diagnosis. Only invasive cancers (ICD-10 codes C00 to C97, excluding C44) are included.

Denominator

The denominator comprises all individuals diagnosed with an invasive cancer (ICD-10 codes C00 to C97, excluding C44) within a five-year period.

Caveats

This dataset uses a simplified methodology that does not replicate the national calculation. As a result, the values reported here may differ from nationally published figures. However, this approach allows for the inclusion of breakdowns by ethnicity, deprivation, and local geography (BSol), which are not always available in national statistics.

External References

For more information, refer to the National Cancer Registration and Analysis Service (NCRAS).

Localities ExplainedThis dataset contains data based on either the resident locality or registered locality of the patient, a distinction is made between resident locality and registered locality populations:Resident Locality refers to individuals who live within the defined geographic boundaries of the locality. These boundaries are aligned with official administrative areas such as wards and Lower Layer Super Output Areas (LSOAs).Registered Locality refers to individuals who are registered with GP practices that are assigned to a locality based on the Primary Care Network (PCN) they belong to. These assignments are approximate—PCNs are mapped to a locality based on the location of most of their GP surgeries. As a result, locality-registered patients may live outside the locality, sometimes even in different towns or cities.This distinction is important because some health indicators are only available at GP practice level, without information on where patients actually reside. In such cases, data is attributed to the locality based on GP registration, not residential address.

Click here to explore more from the Birmingham and Solihull Integrated Care Partnerships Outcome Framework.

Snapshot img

Precision Pathology For Cancer Market Size 2025-2029

The global precision pathology for cancer market is projected to see substantial growth, with an estimated market size and a CAGR of 8.2% during the forecast period. Access detailed market insights upon report purchase. The precision pathology for cancer market is being drives by the rising incidence of cancer and the subsequent demand for enhanced personalized therapies. Digital pathology, boosted by AI and machine learning, enhances diagnostic accuracy, accelerates diagnosis rates, and facilitates therapeutic recommendations, thereby significantly contributing to market expansion. Technological advancements, such as AI tools that improve diagnostic precision and treatment planning in cancer care, are also expected to fuel market growth. The increasing investments in research and development activities will further contribute to market expansion.

To access the full market forecast and comprehensive analysis, Buy Now

How is this market segmented?

The market research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in USD bn for the period 2025-2029, as well as historical data from 2019-2024 for the following segments:

Product

  Consumables
  Instruments


Technology

  Next-Generation Sequencing (NGS)
  Molecular Diagnostics
  Digital Pathology
  Artificial Intelligence (AI) and Machine Learning (ML)
  Liquid Biopsies
  Imaging Technologies


Applications

  Breast Cancer
  Lung Cancer
  Colorectal Cancers
  Prostate Cancer
  Melanoma And Non-Melanoma Skin Cancers


End-use

  Hospitals
  Diagnostic Laboratories
  Research Institutes


APAC

  China
  India
  Japan
  Australia
  Rest of APAC

Europe


  Germany
  Spain
  Italy
  UK
  Rest of Europe

North America


  US
  Canada

South America & MEA


  Brazil
  UAE
  South Africa
  Others





End-use

  Hospitals: Hospitals are key end-users, utilizing precision pathology for in-house diagnostics and treatment planning.
  Research Institutes: Research institutes use precision pathology for cancer research and development of new diagnostic and therapeutic strategies.
  Diagnostic Laboratories: Diagnostic laboratories provide precision pathology services to hospitals and other healthcare providers.


Product

  Consumables: This segment includes antibodies, kits & reagents, and probes used in precision pathology, driven by the increasing volume of diagnostic tests.
  Instruments: This segment encompasses slide staining systems, tissue processing systems, and PCR instruments, crucial for accurate pathological analysis.


Technology

  Liquid Biopsies: Liquid biopsies offer non-invasive methods for detecting cancer biomarkers, aiding in early diagnosis and treatment monitoring.
  Digital Pathology: Digital pathology solutions improve diagnostic accuracy and support therapeutic recommendations, enhancing overall efficiency.
  Imaging Technologies: Imaging technologies like CT, MRI, and ultrasound provide detailed anatomical and functional information for cancer diagnosis and treatment.
  Molecular Diagnostics: Molecular diagnostics are used to detect specific biomarkers and genetic mutations in cancer cells, facilitating targeted therapies.
  Next-Generation Sequencing (NGS): NGS technology is vital for genetic profiling of tumors, enabling personalized treatment strategies.
  Artificial Intelligence (AI) and Machine Learning (ML): AI and ML algorithms aid in analyzing complex pathological data, improving diagnostic precision and treatment planning.


Applications

  Lung Cancer: Genetic profiling helps in selecting appropriate treatments for different types of lung cancer.
  Breast Cancer: Precision pathology is critical in identifying specific subtypes of breast cancer, guiding targeted therapies.
  Prostate Cancer: Precision diagnostics help in determining the aggressiveness of prostate cancer and guiding treatment decisions.
  Colorectal Cancers: Precision pathology aids in identifying genetic mutations that influence treatment response in colorectal cancer.
  Melanoma And Non-Melanoma Skin Cancers: Molecular analysis assists in identifying specific mutations in skin cancers, enabling personalized therapies.

Regional Analysis

APAC: The Asia-Pacific (APAC) region is expected to experience rapid growth in the precision pathology for cancer market, driven by increasing healthcare expenditure, a rising prevalence of cancer, and growing awareness of precision medicine. China and India are key markets in APAC, with significant investments in healthcare infrastructure and a large patient pool, making them major hubs for precision pathology services.
Europe: Europe holds a substantial share of the precision pathology for cancer market, characterized by advanced healthcare systems, a strong focus on research and development, and a high adoption rate of advance

Survival estimates for adults diagnosed with cancer, by stage, for years 2012, 2013, 2014 and 2015, England

National Cancer Registration and Analysis Service (NCRAS). (2019). Cancer Registration: Epidemiology of Melanoma (1995-2017) [Dataset]. Public Health England. https://doi.org/10.25503/n202-3352

Each row represents a C43* tumour. For each tumour the following is provided where available:

• BRESLOW, (Breslow thickness of tumour, Measured in millimetres to the nearest 0.01mm. Can be a number or range, x, or blank (e.g. ≤1mm, 1-2mm)

• diag_quarter (diagnosis quarter is based on the calendar year)

• DIAGNOSISYEAR, (year of diagnosis, 1995-2017)

• ethnicity_band (aggregated in 3 categories: 'White'; 'Non-White' and 'Unknown')

• age_group (aggregated in 3 categories: '<45'; '45-69' and '70+')

• HISTOLOGY_CODED, (histology code - combines the morphology and behaviour codes)

• HISTOLOGY_CODED_DESC, (name for the histology type)

• SEX, (coded as 1=Male and 2=Female)

• SITE_ICD10_O2, (valid 4-digit code, coded in accordance with classification system of The International Classification of Diseases for Oncology) (C430-C439)

• SITE_CODED_DESC, (Site code of the cancer, in the coding system that the tumour was originally coded in and text description)

• T_IMG, (The UICC code which classifies the size and extent of the primary tumour before treatment)

• N_IMG, (The UICC code which classifies the absence or presence and extent of regional lymph node metastases before treatment. +, 0, 1, 1a, 1b, 1c, 1mi, 2, 2a, 2b, 2c, 3, 3a, 3b, 3c, X)

• M_IMG, The UICC code which classifies the absence or presence of distant metastases pre-treatment. 0 = no distant metastasis. 1, 1a, 1b, 1c, 1e = distant metastasis. X = unknown)

• CREG_CODE, (Cancer registry catchment area code (at diagnosis) Y0201 = Northern and Yorkshire Cancer Registry and Information Service; Y0301 = Trent Cancer Registry; Y0401 = Eastern Cancer Registration and Information Centre; Y0801 = Thames Cancer Registry; Y0901 = Oxford Cancer Intelligence Unit; Y1001 = South West Cancer Intelligence Service; Y1101 = Welsh Cancer Intelligence and Surveillance Unit; Y1201 = West Midlands Cancer Intelligence Unit; Y1701 = North West Cancer Intelligence Service; Z9999 = null.

• CREG_NAME, Cancer registry catchment area name (at diagnosis) See above for coding.

• BASISOFDIAGNOSIS, Basis of diagnosis of the tumour according to all the data received by the registry. Non-microscopic: 0 = Death certificate; 1 = Clinical: Diagnosis made before death without (2-7); 2 = Clinical investigation: Includes all diagnostic techniques without a tissue diagnosis; 4 = Specific tumour markers: Includes biochemical and/or immunological markers which are site specific.

Microscopic: 5 = Cytology: Examination of cells whether from a primary or secondary site, including fluids aspirated using endoscopes or needles. Also including microscopic examination of peripheral blood films and trephine bone marrow aspirates; 6 = Histology of a metastases: Includes autopsy specimens; 7 = Histology of a primary tumour: Includes all cutting and bone marrow biopsies. Also includes autopsy specimens of a primary tumour; 9 = Unknown, e.g. PAS or HISS record only.

• MORPH_ICD10_O2, (Morphology of the cancer, in the ICD-10-O2 system)

• BEHAVIOUR_ICD10_O2 Behaviour of the cancer, in the ICD-10-O2 system

• STAGE_BEST, (where stage 1 is coded as 1, 1A, 1A2, 1B, 1C, 1E, 1S; stage 2 is coded as 2, 2A, 2A1, 2B, 2E, 2S; stage 3 is coded as 3, 3A, 3B, 3C, 3E, 3S; stage 4 is coded as 4, 4A, 4B, 4C, 4S; unknown or cannot be stage is coded as 4, 4A, 4B, 4C, 4S; unknown or cannot be staged as 0, 6, ?, U, X, blank)

• STAGE_PATH, (where stage 1 is coded as 1, 1A, 1B, 1E; stage 2 is coded as 2, 2A, 2B, 2E; stage 3 is coded as 3, 3A, 3B; stage 4 is coded as 4, 4A, 4B; unknown or cannot be staged as 0, 6, ?, X, blank)

• GRADE, (Grade of tumour, coded as 3, 4, G1, G2, G3, G4, G5, G6, G7, GX, Unknown or blank)

• CLARKS, (Clark's stage for skin cancer) 1 = melanoma in situ: melanoma cells are only in the epidermis; 2 = melanoma cells in the papillary dermis; 3 = melanoma cells throughout papillary dermis and touching reticula; 4 = melanoma has spread into the reticular or deep dermis; 5 = melanoma has grown into the subcutaneous fat.

• QUINTILE_2015, (Quintile score [1-5], describing income deprivation where 1= least deprived to 5= most deprived)

• DCO (Diagnosis of death certificate only coded as N=No, Y=Yes, blank)

This dataset provides counts of Finished Admission Episodes (FAE) at MSOA level and higher geographies. The information covers the following specified diagnosis, cause and operative procedures: 1) Coronary Heart Disease; 2) Cerbrovascular Disease (including Stroke); 3) Cancer (excluding non-melanoma skin cancer); 4) Falls (basic accidental falls); 5) Coronary Artery Bypass Graft (CABG) and Percutaneous Transluminal Coronary Angioplasty (PTCA) (Heart); 6) Hip Replacement; 7) Knee Replacement; 8) Cataracts. Source: The Information Centre for health and social care (IC) Publisher: Neighbourhood Statistics Geographies: Local Authority District (LAD), Government Office Region (GOR), National Geographic coverage: England Time coverage: 2004/05 to 2007/08 Type of data: Administrative data

According to Cognitive Market Research, the Global Actinic Keratosis market was USD XX Billion in 2023 and is set to achieve a market size of USD XX Billion by the end of 2031 growing at a CAGR of XX% from 2024 to 2031.

North America held the major market share for more than XX% of the global revenue with a market size of USD XX million in 2024 and will grow at a compound annual growth rate (CAGR) of XX % from 2024 to 2031. The Asia Pacific region is the fastest-growing market with a CAGR of XX% from 2024 to 2031 and is projected to grow at a CAGR of XX% in the future. Europe accounted for a market share of over XX% of the global revenue with a USD XX million market size. Latin America had a market share for more than XX% of the global revenue with a market size of USD XX million in 2024 and will grow at a compound annual growth rate (CAGR) of XX% from 2024 to 2031. Middle East and Africa had a market share of around XX% of the global revenue and was estimated at a market size of USD XX million in 2024 and will grow at a compound annual growth rate (CAGR) of XX% from 2024 to 2031. The Actinic Keratosis market held the highest market revenue share in 2024.

Market Dynamics of The Actinic Keratosis Market

Key Drivers for theThe Actinic Keratosis Market

The rising incidence of actinic keratosis fuels the growth of the actinic keratosis treatment market.

Actinic keratosis (AK) is one of the most common diagnoses made by dermatologists, with an estimated prevalence of 13.3% in the European population. In recent years, the incidence of AK has gone up - mainly due to an aging population, and changes in people´s behaviors which lead to increased exposure to UV radiation. It is estimated that about 28%-50% of fair-skinned individuals over 60 years of age are affected by AK, 5 and its incidence continues to increase worldwide. Actinic keratosis if left untreated may develop into a type of non-melanoma skin cancer. Therefore, the rising need for actinic keratosis treatment leads to the growing demand for actinic keratosis treatment market.

For instance, according to Cancer Research UK statistics, Non-melanoma skin cancer incidence rates are projected to rise by 14% in the UK between 2023-2025 and 2038-2040. There could be more than 262,000 new cases of non-melanoma skin cancer every year in the UK by 2038-2040, projections suggest. Source:(https://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/non-melanoma-skin-cancer#heading-Zero)

For instance, according to the British Journal of Dermatology, their comprehensive meta-analysis provides an updated global prevalence rate of actinic keratosis 14%, indicating a significant worldwide disease burden. The incidence rate of actinic keratosis was found to be 1928 per 100,000 PY, emphasizing a growing public health concern. Source:(https://academic.oup.com/bjd/article/190/4/465/7331269) Thus the growing incidence of actinic keratosis cases drives the demand for its treatment thus fuelling the growth of the actinic keratosis market.

Growing awareness campaigns are likely to boost the growth of the actinic keratosis market.

A growing awareness campaign among people about the risks associated with sun exposure and the importance of early detection and treatment of skin conditions like actinic keratosis (AK) is expected to significantly boost the growth of the AK market. As more individuals become informed about the potential consequences of AK, including its link to skin cancer, they are likely to seek medical advice and treatment at earlier stages. This increased awareness not only leads to higher rates of diagnosis but also encourages proactive measures to manage or prevent AK, driving demand for effective treatment options. Additionally, heightened awareness may prompt individuals to undergo regular skin screenings, further contributing to the early detection and treatment of AK, thereby fueling market growth. For instance, in May 2023 Almirall S.A. (ALM), a global biopharmaceutical company focused on medical dermatology, presented today the results of a survey revealing that 85% of respondents are unaware of the existence of actinic keratosis (AK). This chronic skin condition can lead to squamous cell carcinoma (SCC), the second most common form of skin cancer. The survey, conducted by Almirall with over 2,500 participants over the age of 35, aimed to understand th...

Data License

The data is signed off as non-disclosive and is released under an Open Government Licence. link

This work uses data that has been provided by patients and collected by the NHS as part of their care and support. The data are collated, maintained and quality assured by the National Disease Registration Service, which is part of NHS England.

Recommended Reading

A previous project of mine on Kaggle; The benefits of early diagnosis are manifold. As documented in the project, diagnosing cancer in its nascent stages significantly bolsters survival rates, elevates the experience and quality of care received by patients, enhances the overall quality of life, and importantly, drives down both the costs and intricacies associated with cancer treatments. Such benefits underscore the profound importance of prompt diagnosis and also cast a light on the tangible repercussions of delays in such processes.

Cancer is a serious business ! Can technology be leveraged to help an early diagnosis ? link

Introduction

Cancer remains one of the most critical health challenges worldwide, impacting millions and posing substantial burdens on healthcare systems. Early diagnosis is a key factor in improving cancer outcomes, as it allows for timely intervention, often leading to better survival rates and improved quality of life for patients. This project uses data collected by the NHS, managed by the National Disease Registration Service under the Open Government License, to explore patterns in cancer incidence, diagnostic pathways, and survival rates across various cancer types. Through data visualisation and statistical analysis, this work seeks to deepen our understanding of the factors influencing early diagnosis, the effectiveness of different diagnostic routes, and the progression of survival rates over time

Data Visualisation: GDO_data_wide.csv

https://www.googleapis.com/download/storage/v1/b/kaggle-user-content/o/inbox%2F13231939%2Ff9bcb5f75b110bd770d7949f3ceb4066%2FScreenshot%202024-11-13%2012.06.35.png?generation=1731509262231316&alt=media" alt="">

https://www.googleapis.com/download/storage/v1/b/kaggle-user-content/o/inbox%2F13231939%2Fc54f785b479d175ca501a9d8b366c16e%2FScreenshot%202024-11-13%2011.40.59.png?generation=1731509300707188&alt=media" alt="">

The above chart displays the average percentages of different cancer presentation methods across various cancer sites.

Key observations about the chart: - Emergency Presentation (Red): This is a common presentation method for many cancers, especially pancreatic and brain cancers. This likely reflects the difficulty in detecting these cancers early. - GP Referral (Orange): A significant proportion of cancers are diagnosed via GP referral, highlighting the importance of primary care in cancer detection. This is particularly noticeable for skin cancer. - Two-Week Wait (Green): This is most prominent for suspected testicular, prostate, head and neck cancers. - Screening (Blue): Plays a crucial role in detecting specific cancers, notably breast and cervical cancers, where established screening programs exist. However, the impact is small. - Other Outpatient (Purple): This is prominent for eye cancer and varies across other cancer types, likely encompassing a range of planned diagnostic procedures and follow-up appointments.

By combining the information from the chart, we can gain a clearer understanding of how different cancers are typically diagnosed. This information can be valuable for raising awareness, promoting early detection, and improving cancer care.

https://www.googleapis.com/download/storage/v1/b/kaggle-user-content/o/inbox%2F13231939%2F86fec6be22f5c41e884d51d89a9a1acb%2FScreenshot%202024-11-13%2012.10.47.png?generation=1731513024807463&alt=media" alt="">

https://www.googleapis.com/download/storage/v1/b/kaggle-user-content/o/inbox%2F13231939%2F3c3fcf7abefcec3b21f5347cba37b3d5%2FScreenshot%202024-11-13%2012.09.58.png?generation=1731513057381485&alt=media" alt="">

https://www.googleapis.com/download/storage/v1/b/kaggle-user-content/o/inbox%2F13231939%2Fc589ab6f5ed746b15e29ea205db72435%2FScreenshot%202024-11-13%2012.12.13.png?generation=1731513356398140&alt=media" alt="">

https://www.googleapis.com/download/storage/v1/b/kaggle-user-content/o/inbox%2F13231939%2Fb50b4e97250cb9116fb294bd4f0f1350%2FScreenshot%202024-11-13%2012.11.29.png?generation=1731513259601679&alt=media" alt="">

https://www.googleapis.com/download/storage/v1/b/kaggle-user-content/o/inbox%2F13231939%2F058d1b551b886962bb42cc8dd9619b84%2FScreenshot%202024-11-14%2008.58.06.png?generation=1731574947469345&alt=media" alt="">

The cleaned summary tabl...

In the years 2016 to 2020, over ** percent of patients diagnosed with stage one melanoma of the skin in England would survive for at least *** year, while patients with stage one melanoma had a five-year survival rate of over ** percent. The two-year survival rate among those diagnosed with stage four melanoma of the skin was below ** percent.